



US00D912249S

(12) **United States Design Patent**  
**Smith et al.**

(10) **Patent No.:** **US D912,249 S**  
(45) **Date of Patent:** **\*\* Mar. 2, 2021**

- (54) **IMPLANT REMOVAL TOOL**
- (71) Applicant: **Intarcia Therapeutics, Inc.**, Boston, MA (US)
- (72) Inventors: **Jay S. Smith**, Wellesley Hills, MA (US); **Michael R. Cole**, Stratham, NH (US)
- (73) Assignee: **INTARCIA THERAPEUTICS, INC.**, Boston, MA (US)
- (\*\*) Term: **15 Years**
- (21) Appl. No.: **29/699,323**
- (22) Filed: **Jul. 24, 2019**

3,523,906 A 8/1970 Vrancken et al.  
 3,538,916 A 11/1970 Groff et al.  
 3,620,216 A 11/1971 Szymanski  
 (Continued)

**FOREIGN PATENT DOCUMENTS**

EP 0079405 5/1983  
 EP 0254394 1/1988  
 (Continued)

**OTHER PUBLICATIONS**

“Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209211 (Dec. 1994).  
 (Continued)

*Primary Examiner* — Wan Laymon  
 (74) *Attorney, Agent, or Firm* — Brian C. Trinque; Lathrop GPM

**Related U.S. Application Data**

- (62) Division of application No. 29/566,822, filed on Jun. 2, 2016, now Pat. No. Des. 860,451.
- (51) **LOC (13) Cl.** ..... **24-02**
- (52) **U.S. Cl.**  
USPC ..... **D24/143**
- (58) **Field of Classification Search**  
USPC ..... D24/143, 147, 155, 133; D8/57; 604/59-60, 73  
CPC ..... A61M 37/0069  
See application file for complete search history.

(57) **CLAIM**

The ornamental design for an implant removal tool, as shown and described.

**DESCRIPTION**


FIG. 1 is a perspective view of a design for an implant removal tool;  
 FIG. 2 is a front view of the design for the implant removal tool of FIG. 1;  
 FIG. 3 is a back view of the design for the implant removal tool of FIG. 1;  
 FIG. 4 is a first side view of the design for the implant removal tool of FIG. 1;  
 FIG. 5 is a second side view of the design for the implant removal tool of FIG. 1;  
 FIG. 6 is a top view of the design for the implant removal tool of FIG. 1; and,  
 FIG. 7 is a bottom view of the design for the implant removal tool of FIG. 1.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

1,655,158 A 1/1928 Muir  
 2,110,208 A 3/1938 Eggert  
 2,168,437 A 8/1939 Buercklin  
 2,531,724 A 11/1950 Cevasco  
 D179,537 S 1/1957 Floyd et al.  
 3,025,991 A 3/1962 Gillon  
 3,122,162 A 2/1964 Sands  
 3,463,157 A \* 8/1969 Hunt ..... A61D 1/00  
 D24/143

**1 Claim, 7 Drawing Sheets**



(56)

References Cited

U.S. PATENT DOCUMENTS

|               |         |  |             |         |                  |
|---------------|---------|--|-------------|---------|------------------|
| 3,625,214 A   | 12/1971 | Higuchi                                | 4,851,228 A | 7/1989  | Zentner et al.   |
| 3,632,768 A   | 1/1972  | Bergy et al.                           | 4,840,896 A | 9/1989  | Reddy et al.     |
| 3,669,104 A   | 6/1972  | Wyatt et al.                           | 4,865,845 A | 9/1989  | Eckenhoff et al. |
| 3,691,090 A   | 9/1972  | Kitajima et al.                        | 4,871,094 A | 10/1989 | Gall et al.      |
| D226,915 S    | 5/1973  | Huggins                                | 4,873,080 A | 10/1989 | Brickl et al.    |
| 3,732,865 A   | 5/1973  | Higuchi et al.                         | 4,874,388 A | 10/1989 | Wong et al.      |
| 3,737,337 A   | 6/1973  | Schnoring et al.                       | 4,876,781 A | 10/1989 | Balsells         |
| 3,766,915 A   | 10/1973 | Rychlik                                | 4,882,166 A | 11/1989 | Graham et al.    |
| 3,773,919 A   | 11/1973 | Boswell et al.                         | 4,885,166 A | 12/1989 | Meyer et al.     |
| 3,797,492 A   | 3/1974  | Place                                  | 4,886,668 A | 12/1989 | Haslam et al.    |
| 3,869,549 A   | 3/1975  | Geller                                 | 4,892,778 A | 1/1990  | Theeuwes et al.  |
| 3,891,570 A   | 6/1975  | Fukushima et al.                       | 4,893,795 A | 1/1990  | Balsells         |
| D236,035 S    | 7/1975  | Ciencewicki                            | 4,897,471 A | 1/1990  | Stabinsky        |
| 3,960,757 A   | 6/1976  | Morishita et al.                       | 4,907,788 A | 3/1990  | Balsells         |
| 3,987,790 A   | 10/1976 | Eckenhoff et al.                       | 4,915,366 A | 4/1990  | Balsells         |
| 3,995,631 A   | 12/1976 | Higuchi et al.                         | 4,915,949 A | 4/1990  | Wong et al.      |
| 3,995,632 A   | 12/1976 | Nakano et al.                          | 4,915,954 A | 4/1990  | Ayer et al.      |
| 4,008,719 A   | 2/1977  | Theeuwes et al.                        | 4,917,887 A | 4/1990  | Hauptmann et al. |
| 4,034,756 A   | 7/1977  | Higuchi et al.                         | 4,917,895 A | 4/1990  | Lee et al.       |
| 4,078,060 A   | 3/1978  | Benson et al.                          | 4,923,805 A | 5/1990  | Reddy et al.     |
| 4,105,030 A   | 8/1978  | Kercso                                 | 4,927,687 A | 5/1990  | Nuwayser         |
| 4,111,201 A   | 9/1978  | Theeuwes                               | 4,929,554 A | 5/1990  | Goeddel et al.   |
| 4,111,202 A   | 9/1978  | Theeuwes                               | 4,931,285 A | 6/1990  | Edgren et al.    |
| 4,111,203 A   | 9/1978  | Theeuwes                               | 4,934,666 A | 6/1990  | Balsells         |
| 4,203,439 A   | 5/1980  | Theeuwes                               | 4,940,465 A | 7/1990  | Theeuwes et al.  |
| 4,211,771 A   | 7/1980  | Witkowski et al.                       | 4,940,588 A | 7/1990  | Sparks et al.    |
| 4,221,862 A   | 9/1980  | Naito et al.                           | 4,952,402 A | 8/1990  | Sparks et al.    |
| 4,223,674 A   | 9/1980  | Fluent et al.                          | 4,957,119 A | 9/1990  | de Nijs          |
| 4,243,030 A   | 1/1981  | Lynch et al.                           | 4,961,253 A | 10/1990 | Balsells         |
| D258,837 S    | 4/1981  | Spranger et al.                        | 4,964,204 A | 10/1990 | Balsells         |
| D259,458 S    | 6/1981  | Fuller et al.                          | 4,969,884 A | 11/1990 | Yum              |
| 4,305,927 A   | 12/1981 | Theeuwes et al.                        | 4,974,821 A | 12/1990 | Balsells         |
| 4,310,516 A   | 1/1982  | Chang et al.                           | 4,976,966 A | 12/1990 | Theeuwes et al.  |
| 4,340,054 A   | 7/1982  | Michaels                               | 4,994,028 A | 2/1991  | Leonard et al.   |
| 4,350,271 A   | 9/1982  | Eckenhoff                              | 5,004,689 A | 4/1991  | Fiers et al.     |
| 4,373,527 A   | 2/1983  | Fischell                               | 5,006,346 A | 4/1991  | Theeuwes et al.  |
| 4,376,118 A   | 3/1983  | Daher et al.                           | 5,019,382 A | 5/1991  | Cummins, Jr.     |
| 4,384,975 A   | 5/1983  | Fong                                   | 5,019,400 A | 5/1991  | Gombotz et al.   |
| 4,389,330 A   | 9/1983  | Tice et al.                            | 5,023,088 A | 6/1991  | Wong et al.      |
| D271,990 S    | 12/1983 | Lyne                                   | 5,024,842 A | 6/1991  | Edgren et al.    |
| 4,439,196 A   | 3/1984  | Higuchi                                | 5,030,216 A | 7/1991  | Theeuwes et al.  |
| 4,444,498 A   | 4/1984  | Heinemann                              | 5,034,229 A | 7/1991  | Magruder et al.  |
| 4,451,253 A   | 5/1984  | Harman                                 | 5,053,014 A | 10/1991 | Van Heugten      |
| 4,455,143 A   | 6/1984  | Theeuwes et al.                        | 5,057,318 A | 10/1991 | Magruder et al.  |
| 4,455,145 A   | 6/1984  | Theeuwes                               | 5,059,423 A | 10/1991 | Magruder et al.  |
| 4,474,572 A   | 10/1984 | McNaughton et al.                      | 5,066,436 A | 11/1991 | Komen et al.     |
| 4,530,840 A   | 7/1985  | Tice et al.                            | 5,071,642 A | 12/1991 | Lahr et al.      |
| 4,552,561 A   | 11/1985 | Eckenhoff et al.                       | 5,072,070 A | 12/1991 | Balsells         |
| 4,588,614 A   | 5/1986  | Lauchenauer                            | 5,079,388 A | 1/1992  | Balsells         |
| 4,594,108 A   | 6/1986  | Greminger, Jr. et al.                  | 5,090,962 A | 2/1992  | Landry et al.    |
| 4,597,753 A   | 7/1986  | Turley                                 | 5,091,188 A | 2/1992  | Haynes           |
| 4,609,374 A   | 9/1986  | Ayer                                   | 5,108,078 A | 4/1992  | Balsells         |
| 4,639,244 A   | 1/1987  | Rizk et al.                            | 5,110,596 A | 5/1992  | Magruder et al.  |
| 4,655,462 A   | 4/1987  | Balsells                               | 5,112,614 A | 5/1992  | Magruder et al.  |
| 4,657,533 A * | 4/1987  | Oscarsson ..... A61M 37/0069<br>604/60 | 5,113,938 A | 5/1992  | Clayton          |
| 4,673,405 A   | 6/1987  | Guitard et al.                         | 5,117,066 A | 5/1992  | Balsells         |
| 4,675,184 A   | 6/1987  | Hasegawa et al.                        | D326,718 S  | 6/1992  | Maxwell et al.   |
| 4,695,623 A   | 9/1987  | Stabinsky                              | 5,118,666 A | 6/1992  | Habener          |
| 4,727,138 A   | 2/1988  | Goeddel et al.                         | 5,120,306 A | 6/1992  | Gosselin         |
| 4,734,284 A   | 3/1988  | Terada et al.                          | 5,120,712 A | 6/1992  | Habener          |
| 4,737,437 A   | 4/1988  | Gutsell, Jr. et al.                    | 5,120,832 A | 6/1992  | Goeddel et al.   |
| 4,743,449 A   | 5/1988  | Yoshida et al.                         | 5,122,128 A | 6/1992  | Cardinal et al.  |
| 4,753,651 A   | 6/1988  | Eckenhoff                              | 5,122,377 A | 6/1992  | Miller           |
| 4,762,791 A   | 8/1988  | Goeddel et al.                         | 5,126,142 A | 6/1992  | Ayer et al.      |
| 4,765,989 A   | 8/1988  | Wong et al.                            | 5,126,147 A | 6/1992  | Silvestri et al. |
| 4,783,337 A   | 11/1988 | Wong et al.                            | 5,134,244 A | 7/1992  | Balsells         |
| 4,818,517 A   | 4/1989  | Kwee et al.                            | 5,137,727 A | 8/1992  | Eckenhoff        |
| 4,820,267 A   | 4/1989  | Harman                                 | D329,278 S  | 9/1992  | Gallup           |
| 4,820,638 A   | 4/1989  | Swetly et al.                          | 5,147,295 A | 9/1992  | Stewart          |
| 4,826,144 A   | 5/1989  | Balsells                               | 5,151,093 A | 9/1992  | Theeuwes et al.  |
| 4,830,344 A   | 5/1989  | Balsells                               | 5,160,122 A | 11/1992 | Balsells         |
| 4,834,708 A   | 5/1989  | Pillari                                | 5,160,743 A | 11/1992 | Edgren et al.    |
| 4,845,196 A   | 7/1989  | Cowling                                | 5,161,806 A | 11/1992 | Balsells         |
| 4,847,079 A   | 7/1989  | Kwan                                   | 5,180,591 A | 1/1993  | Margruder et al. |
|               |         |  | 5,190,765 A | 3/1993  | Jao et al.       |
|               |         |  | 5,192,273 A | 3/1993  | Bierman          |
|               |         |  | 5,203,849 A | 4/1993  | Balsells         |
|               |         |  | 5,204,108 A | 4/1993  | Illum            |
|               |         |  | 5,207,752 A | 5/1993  | Sorensen et al.  |

(56)

## References Cited

## U.S. PATENT DOCUMENTS

|             |         |                   |             |         |                     |
|-------------|---------|-------------------|-------------|---------|---------------------|
| 5,209,746 A | 5/1993  | Balaban et al.    | 5,542,682 A | 8/1996  | Goldstein et al.    |
| 5,213,809 A | 5/1993  | Wright et al.     | 5,543,156 A | 8/1996  | Roorda et al.       |
| 5,213,810 A | 5/1993  | Steber            | 5,545,618 A | 8/1996  | Buckley et al.      |
| 5,219,572 A | 6/1993  | Sivaramakrishnan  | 5,556,642 A | 9/1996  | Kobayashi et al.    |
| 5,221,278 A | 6/1993  | Linkwitz et al.   | 5,557,318 A | 9/1996  | Gabriel             |
| 5,223,265 A | 6/1993  | Wong              | 5,558,637 A | 9/1996  | Allonen et al.      |
| 5,225,205 A | 7/1993  | Orsolini          | 5,569,289 A | 10/1996 | Yoon                |
| 5,231,176 A | 7/1993  | Goeddel et al.    | 5,571,525 A | 11/1996 | Roorda et al.       |
| 5,234,424 A | 8/1993  | Yum et al.        | 5,574,008 A | 11/1996 | Johnson et al.      |
| 5,234,692 A | 8/1993  | Magruder et al.   | 5,574,137 A | 11/1996 | Gray et al.         |
| 5,234,693 A | 8/1993  | Magruder et al.   | 5,580,578 A | 12/1996 | Oshlack et al.      |
| 5,234,695 A | 8/1993  | Hobbs et al.      | 5,589,167 A | 12/1996 | Cleland et al.      |
| 5,250,026 A | 10/1993 | Ehrlich et al.    | 5,595,751 A | 1/1997  | Bezwada             |
| 5,252,338 A | 10/1993 | Jao et al.        | 5,595,759 A | 1/1997  | Wright et al.       |
| 5,260,069 A | 11/1993 | Chen              | 5,597,579 A | 1/1997  | Bezwada et al.      |
| D342,855 S  | 1/1994  | Butler, II        | 5,602,010 A | 2/1997  | Hauptmann et al.    |
| 5,276,926 A | 1/1994  | Lopez             | 5,605,688 A | 2/1997  | Himmler et al.      |
| 5,278,151 A | 1/1994  | Korb et al.       | 5,607,687 A | 3/1997  | Bezwada et al.      |
| 5,279,544 A | 1/1994  | Gross et al.      | 5,609,885 A | 3/1997  | Rivera et al.       |
| 5,279,554 A | 1/1994  | Turley            | 5,613,954 A | 3/1997  | Nelson et al.       |
| 5,279,555 A | 1/1994  | Lifshey           | 5,614,221 A | 3/1997  | Fjellstrom          |
| 5,279,608 A | 1/1994  | Cherif Cheikh     | 5,614,492 A | 3/1997  | Habener             |
| 5,284,655 A | 2/1994  | Bogdansky et al.  | 5,656,299 A | 3/1997  | Kino et al.         |
| 5,288,501 A | 2/1994  | Numberg et al.    | 5,618,552 A | 4/1997  | Bezwada et al.      |
| 5,288,502 A | 2/1994  | Mcginity et al.   | 5,620,698 A | 4/1997  | Bezwada et al.      |
| 5,290,271 A | 3/1994  | Jernberg          | 5,620,705 A | 4/1997  | Dong et al.         |
| 5,300,079 A | 4/1994  | Niezink et al.    | 5,630,796 A | 5/1997  | Bellhouse et al.    |
| 5,300,302 A | 4/1994  | Tachon et al.     | 5,633,011 A | 5/1997  | Dong et al.         |
| 5,308,348 A | 5/1994  | Balaban et al.    | 5,635,213 A | 6/1997  | Nystrom et al.      |
| 5,312,335 A | 5/1994  | McKinnon et al.   | 5,639,477 A | 6/1997  | Maruyama et al.     |
| 5,312,389 A | 5/1994  | Theeuwes et al.   | 5,639,640 A | 6/1997  | Reddy et al.        |
| 5,312,390 A | 5/1994  | Wong              | 5,645,850 A | 7/1997  | Bezwada et al.      |
| 5,318,558 A | 6/1994  | Linkwitz et al.   | 5,648,088 A | 7/1997  | Bezwada et al.      |
| 5,318,780 A | 6/1994  | Viegas et al.     | 5,650,173 A | 7/1997  | Ramstack et al.     |
| 5,320,616 A | 6/1994  | Magndu et al.     | 5,654,008 A | 8/1997  | Herbert et al.      |
| 5,324,280 A | 6/1994  | Wong et al.       | 5,654,010 A | 8/1997  | Johnson et al.      |
| 5,336,057 A | 8/1994  | Fukuda et al.     | 5,656,297 A | 8/1997  | Bernstein et al.    |
| 5,336,505 A | 8/1994  | Ng et al.         | 5,658,593 A | 8/1997  | Orly et al.         |
| 5,348,544 A | 9/1994  | Sweeney et al.    | 5,660,847 A | 8/1997  | Magruder et al.     |
| 5,352,662 A | 10/1994 | Brooks et al.     | 5,660,858 A | 8/1997  | Parikh et al.       |
| 5,368,588 A | 11/1994 | Bettinger         | 5,660,861 A | 8/1997  | Jao et al.          |
| 5,368,863 A | 11/1994 | Eckenhoff et al.  | 5,667,808 A | 9/1997  | Johnson et al.      |
| 5,371,089 A | 12/1994 | Rattan            | 5,668,170 A | 9/1997  | Gyory               |
| 5,374,620 A | 12/1994 | Clark et al.      | 5,672,549 A | 9/1997  | Minami et al.       |
| 5,385,738 A | 1/1995  | Yamahira et al.   | 5,676,942 A | 10/1997 | Testa et al.        |
| 5,385,887 A | 1/1995  | Yim et al.        | 5,686,097 A | 11/1997 | Taskovich et al.    |
| 5,395,319 A | 3/1995  | Hirsch et al.     | 5,688,801 A | 11/1997 | Mesens et al.       |
| 5,407,609 A | 4/1995  | Tice et al.       | 5,690,925 A | 11/1997 | Gray et al.         |
| D358,644 S  | 5/1995  | Park              | 5,690,952 A | 11/1997 | Magruder et al.     |
| 5,411,951 A | 5/1995  | Mitchell          | 5,695,463 A | 12/1997 | Cherif-Cheikh       |
| 5,413,572 A | 5/1995  | Wong et al.       | 5,697,113 A | 12/1997 | Shatz et al.        |
| 5,413,672 A | 5/1995  | Hirotsuji et al.  | 5,697,914 A | 12/1997 | Brimhall            |
| 5,424,286 A | 6/1995  | Eng               | 5,698,213 A | 12/1997 | Jamiolkowski et al. |
| 5,428,024 A | 6/1995  | Chu et al.        | 5,700,486 A | 12/1997 | Canal et al.        |
| 5,429,602 A | 7/1995  | Hauser            | 5,700,583 A | 12/1997 | Jamiolkowski et al. |
| 5,439,688 A | 8/1995  | Orsolini et al.   | 5,703,200 A | 12/1997 | Bezwada et al.      |
| 5,443,459 A | 8/1995  | Wong et al.       | 5,707,644 A | 1/1998  | Illum               |
| 5,445,829 A | 8/1995  | Paradissis et al. | 5,711,967 A | 1/1998  | Juch                |
| 5,456,679 A | 10/1995 | Balaban et al.    | 5,713,847 A | 2/1998  | Howard, III et al.  |
| 5,458,888 A | 10/1995 | Chen              | 5,718,922 A | 2/1998  | Herrero-Vanrell     |
| 5,464,929 A | 11/1995 | Bezwada et al.    | 5,725,497 A | 3/1998  | Woodruff et al.     |
| 5,472,708 A | 12/1995 | Chen              | 5,728,088 A | 3/1998  | Margruder et al.    |
| 5,478,564 A | 12/1995 | Wantier et al.    | 5,728,396 A | 3/1998  | Peery et al.        |
| 5,484,403 A | 1/1996  | Yoakum et al.     | 5,733,572 A | 3/1998  | Unger et al.        |
| 5,486,365 A | 1/1996  | Takado et al.     | 5,736,159 A | 4/1998  | Chen et al.         |
| 5,498,255 A | 3/1996  | Wong et al.       | 5,738,845 A | 4/1998  | Imakawa             |
| 5,511,355 A | 4/1996  | Dingler           | 5,747,058 A | 5/1998  | Tipton et al.       |
| 5,512,293 A | 4/1996  | Landrau et al.    | 5,756,450 A | 5/1998  | Hahn et al.         |
| 5,512,549 A | 4/1996  | Chen et al.       | 5,767,251 A | 6/1998  | Reddy et al.        |
| 5,514,110 A | 5/1996  | Teh               | 5,770,231 A | 6/1998  | Mesens et al.       |
| 5,529,914 A | 6/1996  | Hubbell et al.    | 5,782,396 A | 7/1998  | Mastri et al.       |
| 5,531,736 A | 7/1996  | Wong et al.       | 5,792,477 A | 8/1998  | Rickey et al.       |
| 5,540,665 A | 7/1996  | Mercado et al.    | 5,795,591 A | 8/1998  | Lee et al.          |
| 5,540,912 A | 7/1996  | Roorda et al.     | 5,795,779 A | 8/1998  | McCormick et al.    |
| 5,541,172 A | 7/1996  | Labrie et al.     | 5,807,876 A | 9/1998  | Armistead et al.    |
|             |         |                   | 5,810,769 A | 9/1998  | Schlegel et al.     |
|             |         |                   | 5,814,323 A | 9/1998  | Lyle                |
|             |         |                   | D399,821 S  | 10/1998 | Tyneski             |
|             |         |                   | 5,817,129 A | 10/1998 | Labrecque et al.    |

(56)

References Cited

U.S. PATENT DOCUMENTS

|              |         |                     |                |         |                     |              |
|--------------|---------|---------------------|----------------|---------|---------------------|--------------|
| 5,827,297 A  | 10/1998 | Boudjema            | 6,174,547 B1   | 1/2001  | Dong et al.         |              |
| 5,830,501 A  | 11/1998 | Dong et al.         | 6,177,096 B1   | 1/2001  | Zerbe et al.        |              |
| 5,836,935 A  | 11/1998 | Ashton et al.       | 6,183,461 B1   | 2/2001  | Matsuura et al.     |              |
| 5,843,891 A  | 12/1998 | Sherman             | 6,187,095 B1   | 2/2001  | Labrecque et al.    |              |
| 5,844,017 A  | 12/1998 | Jamiolkowski et al. | 6,190,350 B1 * | 2/2001  | Davis .....         | A61M 37/0069 |
| 5,851,451 A  | 12/1998 | Takechi et al.      |                |         |                     | 604/61       |
| 5,858,746 A  | 1/1999  | Hubbell et al.      | 6,190,700 B1   | 2/2001  | Okada et al.        |              |
| 5,859,150 A  | 1/1999  | Jamiolkowski et al. | 6,190,702 B1   | 2/2001  | Takada et al.       |              |
| 5,861,166 A  | 1/1999  | Eckenhoff           | 6,191,102 B1   | 2/2001  | DiMarchi et al.     |              |
| 5,871,770 A  | 2/1999  | Margruder et al.    | 6,204,022 B1   | 3/2001  | Johnson et al.      |              |
| 5,871,778 A  | 2/1999  | Kino et al.         | 6,217,893 B1   | 4/2001  | Pellet et al.       |              |
| 5,874,388 A  | 2/1999  | Hsu                 | 6,217,906 B1   | 4/2001  | Gumucio et al.      |              |
| 5,876,746 A  | 3/1999  | Jona et al.         | 6,217,908 B1   | 4/2001  | Mathiowitz et al.   |              |
| 5,882,676 A  | 3/1999  | Lee et al.          | 6,218,431 B1   | 4/2001  | Schoen et al.       |              |
| D408,917 S   | 4/1999  | Hacker              | 6,224,894 B1   | 5/2001  | Jamiolkowski et al. |              |
| 5,904,935 A  | 5/1999  | Eckenhoff et al.    | 6,235,712 B1   | 5/2001  | Stevenson et al.    |              |
| 5,906,599 A  | 5/1999  | Kaldany             | 6,245,349 B1   | 6/2001  | Yiv et al.          |              |
| 5,906,816 A  | 5/1999  | Soos et al.         | 6,245,357 B1   | 6/2001  | Edgren et al.       |              |
| 5,906,830 A  | 5/1999  | Farinas et al.      | 6,248,112 B1   | 6/2001  | Gambale et al.      |              |
| 5,908,621 A  | 6/1999  | Glue et al.         | 6,251,435 B1   | 6/2001  | Jamiolkowski et al. |              |
| 5,916,598 A  | 6/1999  | Rickey et al.       | D445,975 S     | 7/2001  | Stratford           |              |
| 5,922,253 A  | 7/1999  | Herbert et al.      | 6,258,377 B1   | 7/2001  | New et al.          |              |
| 5,928,666 A  | 7/1999  | Farinas et al.      | 6,261,584 B1   | 7/2001  | Peery et al.        |              |
| 5,932,547 A  | 8/1999  | Stevenson et al.    | 6,268,343 B1   | 7/2001  | Knudsen et al.      |              |
| 5,938,654 A  | 8/1999  | Wong et al.         | 6,270,700 B1   | 8/2001  | Ignatious           |              |
| 5,939,286 A  | 8/1999  | Johnson et al.      | 6,270,787 B1   | 8/2001  | Ayer                |              |
| 5,942,223 A  | 8/1999  | Bazer et al.        | 6,277,413 B1   | 8/2001  | Sankaram            |              |
| 5,942,253 A  | 8/1999  | Gombotz et al.      | 6,283,949 B1   | 9/2001  | Roorda              |              |
| 5,945,126 A  | 8/1999  | Thanoo et al.       | 6,284,264 B1   | 9/2001  | Zerbe et al.        |              |
| 5,948,430 A  | 9/1999  | Zerbe et al.        | 6,284,727 B1   | 9/2001  | Kim et al.          |              |
| 5,951,521 A  | 9/1999  | Mastrototaro et al. | 6,287,295 B1   | 9/2001  | Chen et al.         |              |
| 5,958,909 A  | 9/1999  | Habener             | 6,284,725 B1   | 12/2001 | Coolidge et al.     |              |
| D415,073 S   | 10/1999 | Meehan et al.       | 6,329,336 B1   | 12/2001 | Bridon et al.       |              |
| 5,962,023 A  | 10/1999 | Jamiolkowski et al. | 6,331,311 B1   | 12/2001 | Brodbeck et al.     |              |
| 5,965,168 A  | 10/1999 | Mesens et al.       | 6,372,218 B1   | 4/2002  | Cummins, Jr.        |              |
| 5,972,370 A  | 10/1999 | Eckenhoff et al.    | 6,372,256 B2   | 4/2002  | Jamiolkowski et al. |              |
| 5,972,373 A  | 10/1999 | Yajima et al.       | 6,375,978 B1   | 4/2002  | Kleiner et al.      |              |
| 5,976,109 A  | 11/1999 | Heruth              | D456,776 S     | 5/2002  | Lindekugel          |              |
| 5,980,945 A  | 11/1999 | Ruiz                | 6,395,282 B1   | 5/2002  | Kende et al.        |              |
| 5,981,719 A  | 11/1999 | Woiszwillo et al.   | 6,395,292 B2   | 5/2002  | Peery et al.        |              |
| 5,984,890 A  | 11/1999 | Gast et al.         | 6,402,716 B1   | 6/2002  | Ryoo et al.         |              |
| 5,985,305 A  | 11/1999 | Peery et al.        | 6,403,655 B1   | 6/2002  | Bezwada et al.      |              |
| 5,989,463 A  | 11/1999 | Tracy et al.        | 6,419,952 B2   | 7/2002  | Wong et al.         |              |
| 5,997,527 A  | 12/1999 | Gumucio et al.      | 6,428,517 B1   | 8/2002  | Hochman et al.      |              |
| 5,997,902 A  | 12/1999 | Maruyama et al.     | 6,433,144 B1   | 8/2002  | Morris et al.       |              |
| 6,007,805 A  | 12/1999 | Foster et al.       | 6,436,091 B1   | 8/2002  | Harper et al.       |              |
| 6,017,545 A  | 1/2000  | Modi                | 6,447,522 B2   | 9/2002  | Gambale et al.      |              |
| 6,022,561 A  | 2/2000  | Carlsson et al.     | 6,451,974 B1   | 9/2002  | Hansen              |              |
| 6,023,802 A  | 2/2000  | King                | 6,458,385 B2   | 10/2002 | Jamiolkowski et al. |              |
| 6,029,361 A  | 2/2000  | Newman              | 6,458,387 B1   | 10/2002 | Scott et al.        |              |
| 6,053,927 A  | 4/2000  | Hamas               | 6,458,924 B2   | 10/2002 | Knudsen et al.      |              |
| 6,056,718 A  | 5/2000  | Funderburk et al.   | 6,461,605 B1   | 10/2002 | Cutler et al.       |              |
| 6,060,450 A  | 5/2000  | Soos et al.         | 6,464,688 B1   | 10/2002 | Harper et al.       |              |
| 6,069,133 A  | 5/2000  | Carlo et al.        | 6,468,961 B1   | 10/2002 | Brodbeck et al.     |              |
| 6,074,377 A  | 6/2000  | Sanfilippo, II      | 6,471,688 B1   | 10/2002 | Harper et al.       |              |
| 6,074,660 A  | 6/2000  | Jamiolkowski et al. | 6,472,512 B1   | 10/2002 | LaFleur et al.      |              |
| 6,074,673 A  | 6/2000  | Guillen             | 6,478,768 B1   | 11/2002 | Kneer               |              |
| 6,100,346 A  | 8/2000  | Jamiolkowski et al. | 6,485,706 B1   | 11/2002 | McCoy et al.        |              |
| 6,110,503 A  | 8/2000  | Rickey et al.       | 6,495,164 B1   | 12/2002 | Ramstack et al.     |              |
| D430,671 S   | 9/2000  | Shute               | 6,506,724 B1   | 1/2003  | Hiles et al.        |              |
| 6,113,938 A  | 9/2000  | Chen et al.         | 6,508,808 B1   | 1/2003  | Carr et al.         |              |
| 6,113,947 A  | 9/2000  | Cleland et al.      | 6,514,500 B1   | 2/2003  | Bridon et al.       |              |
| 6,120,787 A  | 9/2000  | Gustafsson et al.   | 6,514,517 B2   | 2/2003  | Jamiolkowski et al. |              |
| 6,124,261 A  | 9/2000  | Stevenson et al.    | 6,524,305 B1   | 2/2003  | Peterson et al.     |              |
| 6,124,281 A  | 9/2000  | Lewis et al.        | 6,528,093 B1   | 3/2003  | Kamei et al.        |              |
| 6,127,520 A  | 10/2000 | Ueda et al.         | 6,528,486 B1   | 3/2003  | Larsen et al.       |              |
| 6,129,761 A  | 10/2000 | Hubbell             | D472,896 S     | 4/2003  | Peiker              |              |
| 6,130,200 A  | 10/2000 | Brodbeck et al.     | 6,541,021 B1   | 4/2003  | Johnson et al.      |              |
| 6,132,420 A  | 10/2000 | Dionne et al.       | 6,544,239 B2   | 4/2003  | Kinsey et al.       |              |
| 6,133,249 A  | 10/2000 | Hills               | 6,544,252 B1   | 4/2003  | Theeuwes et al.     |              |
| 6,133,429 A  | 10/2000 | Davis et al.        | 6,547,250 B1   | 4/2003  | Noble et al.        |              |
| 6,146,139 A  | 11/2000 | Harrison, III       | 6,551,613 B1   | 4/2003  | Dong et al.         |              |
| 6,147,168 A  | 11/2000 | Jamiolkowski et al. | 6,569,420 B2   | 5/2003  | Chen et al.         |              |
| 6,156,331 A  | 12/2000 | Peery et al.        | 6,572,890 B2   | 6/2003  | Faour et al.        |              |
| 6,172,046 B1 | 1/2001  | Albrecht            | 6,579,851 B2   | 6/2003  | Goeke et al.        |              |
|              |         |                     | 6,589,157 B2   | 7/2003  | Fontayne et al.     |              |
|              |         |                     | 6,592,508 B1   | 7/2003  | Ravins et al.       |              |
|              |         |                     | 6,592,887 B2   | 7/2003  | Zerbe et al.        |              |
|              |         |                     | 6,593,295 B2   | 7/2003  | Bridon et al.       |              |

(56)

References Cited

U.S. PATENT DOCUMENTS

|              |         |                   |                |         |                                     |
|--------------|---------|-------------------|----------------|---------|-------------------------------------|
| 6,607,529 B1 | 8/2003  | Jones et al.      | 7,521,423 B2   | 4/2009  | Young et al.                        |
| 6,626,863 B1 | 9/2003  | Berler            | 7,563,871 B2   | 7/2009  | Wright et al.                       |
| 6,635,268 B2 | 10/2003 | Peery et al.      | 7,589,169 B2   | 9/2009  | Bolotin                             |
| 6,645,192 B2 | 11/2003 | Kenison et al.    | 7,604,647 B2   | 10/2009 | Chen                                |
| 6,667,061 B2 | 12/2003 | Ramstack et al.   | 7,612,176 B2   | 11/2009 | Wright et al.                       |
| 6,670,368 B1 | 12/2003 | Breault et al.    | 7,632,256 B2   | 12/2009 | Mosier et al.                       |
| 6,673,767 B1 | 1/2004  | Brodbeck et al.   | 7,635,463 B2   | 12/2009 | Bolotin et al.                      |
| 6,682,522 B2 | 1/2004  | Carr et al.       | D608,447 S     | 1/2010  | Meyer                               |
| 6,703,225 B1 | 3/2004  | Kojima et al.     | 7,655,254 B2   | 2/2010  | Dennis et al.                       |
| 6,703,359 B1 | 3/2004  | Young et al.      | 7,655,257 B2   | 2/2010  | Peery et al.                        |
| 6,706,689 B2 | 3/2004  | Coolidge et al.   | 7,666,835 B2   | 2/2010  | Bloom et al.                        |
| 6,709,671 B2 | 3/2004  | Zerbe et al.      | 7,682,356 B2   | 3/2010  | Alessi et al.                       |
| 6,720,407 B1 | 4/2004  | Hughes et al.     | 7,727,519 B2   | 6/2010  | Moran                               |
| 6,730,328 B2 | 5/2004  | Maskiwicz et al.  | 7,731,947 B2   | 6/2010  | Eliasz et al.                       |
| 6,752,753 B1 | 6/2004  | Hoskins et al.    | 7,736,665 B2   | 6/2010  | Patel et al.                        |
| D492,995 S * | 7/2004  | Rue ..... D24/133 | 7,741,269 B2   | 6/2010  | Young et al.                        |
| 6,767,887 B1 | 7/2004  | Hoffmann et al.   | 7,766,924 B1   | 8/2010  | Bombard et al.                      |
| 6,821,949 B2 | 11/2004 | Bridon et al.     | 7,790,140 B2   | 9/2010  | Bolotin                             |
| 6,833,256 B1 | 12/2004 | Pontzer et al.    | 7,825,091 B2   | 11/2010 | Bloom et al.                        |
| 6,835,194 B2 | 12/2004 | Johnson et al.    | 7,829,109 B2   | 11/2010 | Chen et al.                         |
| 6,840,931 B2 | 1/2005  | Peterson et al.   | 7,833,543 B2   | 11/2010 | Gibson et al.                       |
| 6,849,708 B1 | 2/2005  | Habener           | 7,879,028 B2   | 2/2011  | Alessi et al.                       |
| 6,849,714 B1 | 2/2005  | Bridon et al.     | 7,879,794 B2   | 4/2011  | Weyer et al.                        |
| 6,858,576 B1 | 2/2005  | Young et al.      | 7,919,109 B2   | 4/2011  | Berry et al.                        |
| 6,872,700 B1 | 3/2005  | Young et al.      | D638,478 S     | 5/2011  | Block                               |
| 6,875,748 B2 | 4/2005  | Manthorpe et al.  | 7,928,065 B2   | 6/2011  | Young et al.                        |
| 6,887,470 B1 | 5/2005  | Bridon et al.     | 7,964,183 B2   | 6/2011  | Eliasz et al.                       |
| 6,887,849 B2 | 5/2005  | Bridon et al.     | 8,039,432 B2   | 10/2011 | Bridon et al.                       |
| 6,899,398 B2 | 5/2005  | Albayrak          | 7,959,938 B2   | 11/2011 | Rohloff et al.                      |
| 6,899,887 B2 | 5/2005  | Ayer              | 8,048,438 B2   | 11/2011 | Berry et al.                        |
| 6,902,744 B1 | 6/2005  | Kolterman et al.  | 8,052,996 B2   | 11/2011 | Lautenbach et al.                   |
| 6,903,186 B1 | 6/2005  | Dong              | 8,058,233 B2   | 11/2011 | Cowley et al.                       |
| 6,913,767 B1 | 7/2005  | Cleland et al.    | 8,101,576 B2   | 1/2012  | Bloom                               |
| 6,923,800 B2 | 8/2005  | Chen et al.       | 8,114,430 B2   | 2/2012  | Rohloff et al.                      |
| 6,924,264 B1 | 8/2005  | Prickett et al.   | 8,114,437 B2   | 2/2012  | Rohloff et al.                      |
| 6,939,556 B2 | 9/2005  | Lautenbach        | 8,158,150 B2   | 4/2012  | Lautenbach et al.                   |
| 6,956,026 B2 | 10/2005 | Beeley et al.     | 8,173,150 B2   | 5/2012  | Berry et al.                        |
| 6,960,192 B1 | 11/2005 | Flaherty et al.   | 8,202,836 B2   | 6/2012  | Moore et al.                        |
| 6,969,702 B2 | 11/2005 | Bertilsson et al. | 8,206,745 B2   | 6/2012  | Rohloff et al.                      |
| 6,976,981 B2 | 12/2005 | Ayer              | 8,211,467 B2   | 7/2012  | Rohloff et al.                      |
| 6,989,366 B2 | 1/2006  | Beeley et al.     | 8,217,001 B2   | 7/2012  | Cowley et al.                       |
| 6,992,065 B2 | 1/2006  | Okumu             | 8,231,859 B2   | 7/2012  | Bolotin et al.                      |
| 6,997,922 B2 | 2/2006  | Theeuwes et al.   | 8,251,946 B2   | 8/2012  | Bardy                               |
| 7,008,439 B1 | 3/2006  | Janzen et al.     | 8,257,682 B2   | 9/2012  | Bolotin et al.                      |
| 7,014,636 B2 | 3/2006  | Gilbert           | 8,257,691 B2   | 9/2012  | Eliasz et al.                       |
| 7,022,674 B2 | 4/2006  | DeFelippis et al. | 8,262,667 B1 * | 9/2012  | Silver ..... A61F 2/4603<br>606/207 |
| 7,041,646 B2 | 5/2006  | Pan et al.        | 8,263,545 B2   | 9/2012  | Levy et al.                         |
| 7,074,423 B2 | 7/2006  | Fereira et al.    | 8,263,736 B2   | 9/2012  | Berry                               |
| 7,084,243 B2 | 8/2006  | Glaesner et al.   | 8,268,341 B2   | 9/2012  | Berry                               |
| 7,101,567 B1 | 9/2006  | Sano et al.       | 8,273,365 B2   | 9/2012  | Lautenbach et al.                   |
| 7,101,843 B2 | 9/2006  | Glaesner et al.   | 8,273,713 B2   | 9/2012  | Pittner et al.                      |
| 7,112,335 B2 | 9/2006  | Lautenbach        | D669,589 S     | 10/2012 | Delaey                              |
| 7,115,569 B2 | 10/2006 | Beeley et al.     | 8,277,776 B2   | 10/2012 | Boiotin et al.                      |
| 7,138,375 B2 | 11/2006 | Beeley et al.     | 8,278,267 B2   | 10/2012 | Weyer et al.                        |
| 7,138,486 B2 | 11/2006 | Habener et al.    | 8,288,338 B2   | 10/2012 | Young et al.                        |
| 7,141,547 B2 | 11/2006 | Rosen et al.      | 8,298,561 B2   | 10/2012 | Alessi et al.                       |
| 7,144,863 B2 | 12/2006 | DeFelippis et al. | 8,299,025 B2   | 10/2012 | Alessi et al.                       |
| 7,153,825 B2 | 12/2006 | Young et al.      | 8,343,140 B2   | 1/2013  | Alessi et al.                       |
| 7,157,555 B1 | 1/2007  | Beeley et al.     | 8,367,095 B2   | 2/2013  | Lautenbach et al.                   |
| 7,163,688 B2 | 1/2007  | Peery et al.      | 8,372,424 B2   | 2/2013  | Berry et al.                        |
| 7,163,697 B2 | 1/2007  | Hanes et al.      | D678,889 S     | 3/2013  | Chiu                                |
| 7,199,217 B2 | 4/2007  | DiMarchi et al.   | 8,398,967 B2   | 3/2013  | Eliasz et al.                       |
| 7,205,409 B2 | 4/2007  | Pei et al.        | 8,440,226 B2   | 5/2013  | Rohloff et al.                      |
| 7,207,982 B2 | 4/2007  | Dionne et al.     | 8,454,552 B2   | 6/2013  | Bardy                               |
| 7,214,206 B2 | 5/2007  | Rue et al.        | 8,460,694 B2   | 6/2013  | Rohloff et al.                      |
| 7,241,457 B2 | 7/2007  | Chen et al.       | 8,470,353 B2   | 6/2013  | Lautenbach et al.                   |
| 7,258,869 B1 | 8/2007  | Berry et al.      | 8,556,861 B2   | 10/2013 | Tsals                               |
| D555,589 S   | 11/2007 | Hussaini et al.   | 8,722,037 B2   | 5/2014  | Veenstra et al.                     |
| 7,297,761 B2 | 11/2007 | Beeley et al.     | 8,747,412 B2   | 6/2014  | Bae et al.                          |
| 7,316,680 B2 | 1/2008  | Gilbert           | 8,801,700 B2   | 8/2014  | Alessi et al.                       |
| 7,393,827 B2 | 7/2008  | Nadler            | 8,815,802 B2   | 8/2014  | Kalthoff et al.                     |
| 7,407,499 B2 | 8/2008  | Trautman          | 8,845,726 B2   | 9/2014  | Tebbe                               |
| 7,442,682 B2 | 10/2008 | Kitaura et al.    | 8,858,621 B2   | 10/2014 | Oba et al.                          |
| 7,456,254 B2 | 11/2008 | Wright et al.     | 8,865,202 B2   | 10/2014 | Zerbe et al.                        |
| 7,459,432 B2 | 12/2008 | Cowley et al.     | 8,888,745 B2   | 11/2014 | Van Der Graaf et al.                |
|              |         |                   | 8,926,595 B2   | 1/2015  | Alessi et al.                       |
|              |         |                   | 8,940,316 B2   | 1/2015  | Alessi et al.                       |
|              |         |                   | 8,992,961 B2   | 3/2015  | Berry et al.                        |

(56)

References Cited

U.S. PATENT DOCUMENTS

|                 |         |                     |                  |         |                                   |
|-----------------|---------|---------------------|------------------|---------|-----------------------------------|
| 8,992,962 B2    | 3/2015  | Lautenbach et al.   | 2004/0024068 A1  | 2/2004  | Levy et al.                       |
| 9,044,209 B2    | 6/2015  | Dayton et al.       | 2004/0024069 A1  | 2/2004  | Chen et al.                       |
| 9,078,900 B2    | 7/2015  | Kuzma et al.        | 2004/0029784 A1  | 2/2004  | Hathaway                          |
| 9,095,553 B2    | 8/2015  | Rohloff et al.      | 2004/0039376 A1  | 2/2004  | Peery et al.                      |
| 9,241,722 B2    | 1/2016  | Yu                  | 2004/0047888 A1  | 3/2004  | Kenison et al.                    |
| D750,764 S      | 3/2016  | DeSocio             | 2004/0097906 A1  | 5/2004  | Fereira et al.                    |
| 9,332,995 B2    | 5/2016  | Russo et al.        | 2004/0101557 A1  | 5/2004  | Gibson et al.                     |
| 9,526,763 B2    | 12/2016 | Rohloff et al.      | 2004/0102762 A1  | 5/2004  | Gilbert                           |
| 9,539,200 B2    | 1/2017  | Lautenbach          | 2004/0115236 A1  | 6/2004  | Chan et al.                       |
| 9,572,889 B2    | 2/2017  | Alessi et al.       | 2004/0142867 A1  | 7/2004  | Oi et al.                         |
| D789,539 S      | 6/2017  | Kleiner et al.      | 2004/0142902 A1  | 7/2004  | Struijker-Boudier                 |
| D789,540 S      | 6/2017  | Gyorgy              | 2004/0151753 A1  | 8/2004  | Chen et al.                       |
| 9,682,127 B2    | 6/2017  | Alessi et al.       | 2004/0157951 A1  | 8/2004  | Wolf                              |
| RE46,577 E      | 10/2017 | Collins et al.      | 2004/0198654 A1  | 10/2004 | Glaesner et al.                   |
| D805,199 S      | 12/2017 | Chen et al.         | 2004/0199140 A1* | 10/2004 | Rue ..... A61M 37/0069<br>604/506 |
| D810,289 S      | 2/2018  | Jutila et al.       | 2004/0209801 A1  | 10/2004 | Brand et al.                      |
| 9,889,085 B1    | 2/2018  | Alessi et al.       | 2004/0215133 A1  | 10/2004 | Weber et al.                      |
| D816,843 S      | 5/2018  | Lewis               | 2004/0224903 A1  | 11/2004 | Berry et al.                      |
| D819,820 S      | 6/2018  | Radau et al.        | 2004/0225113 A1  | 11/2004 | LaFleur et al.                    |
| 10,314,617 B2   | 6/2019  | Bratlie             | 2004/0243106 A1  | 12/2004 | Ayer                              |
| 2001/0012511 A1 | 8/2001  | Bezwada et al.      | 2004/0265273 A1  | 12/2004 | Li et al.                         |
| 2001/0021377 A1 | 9/2001  | Jamiolkowski et al. | 2004/0266683 A1  | 12/2004 | Hathaway et al.                   |
| 2001/0021822 A1 | 9/2001  | Ayer                | 2004/0266692 A1  | 12/2004 | Young et al.                      |
| 2001/0022974 A1 | 9/2001  | Ayer                | 2005/0004557 A1  | 1/2005  | Russell                           |
| 2001/0026793 A1 | 10/2001 | Jamiolkowski et al. | 2005/0008661 A1  | 1/2005  | Fereira et al.                    |
| 2001/0027311 A1 | 10/2001 | Chen et al.         | 2005/0009742 A1  | 1/2005  | Bertilsson et al.                 |
| 2001/0031940 A1 | 10/2001 | Loos                | 2005/0010196 A1  | 1/2005  | Fereira et al.                    |
| 2001/0031790 A1 | 11/2001 | Beisswenger         | 2005/0010942 A1  | 1/2005  | Kim et al.                        |
| 2001/0036472 A1 | 11/2001 | Wong et al.         | 2005/0070883 A1  | 3/2005  | Brown et al.                      |
| 2001/0040326 A1 | 11/2001 | Balczun             | 2005/0070927 A1  | 3/2005  | Feinberg                          |
| 2002/0001631 A1 | 1/2002  | Okumu               | 2005/0079200 A1  | 4/2005  | Rathenow et al.                   |
| 2002/0004481 A1 | 1/2002  | Cleland et al.      | 2005/0079202 A1  | 4/2005  | Chen et al.                       |
| 2002/0012818 A1 | 1/2002  | Ruppi et al.        | 2005/0095284 A1  | 5/2005  | Trautman                          |
| 2002/0034532 A1 | 3/2002  | Brodbeck et al.     | 2005/0101943 A1  | 5/2005  | Ayer et al.                       |
| 2002/0037309 A1 | 3/2002  | Jaworowicz et al.   | 2005/0106214 A1  | 5/2005  | Chen                              |
| 2002/0048600 A1 | 4/2002  | Bhatt et al.        | 2005/0112188 A1  | 5/2005  | Eliasz et al.                     |
| 2002/0077599 A1 | 6/2002  | Wojcik              | 2005/0118206 A1  | 6/2005  | Luk et al.                        |
| 2002/0098180 A1 | 7/2002  | Lei et al.          | 2005/0118221 A1  | 6/2005  | Blakely et al.                    |
| 2002/0136848 A1 | 9/2002  | Yoshii et al.       | 2005/0131386 A1  | 6/2005  | Freeman et al.                    |
| 2002/0137666 A1 | 9/2002  | Beeley et al.       | 2005/0131389 A1  | 6/2005  | Peterson et al.                   |
| 2002/0141985 A1 | 10/2002 | Pittner et al.      | 2005/0143749 A1  | 6/2005  | Zalenskiet et al.                 |
| 2002/0197185 A1 | 12/2002 | Jamiolkowski et al. | 2005/0175701 A1  | 8/2005  | Pan et al.                        |
| 2002/0197235 A1 | 12/2002 | Moran               | 2005/0201980 A1  | 9/2005  | Moran                             |
| 2003/0007992 A1 | 1/2003  | Gibson et al.       | 2005/0215475 A1  | 9/2005  | Ong et al.                        |
| 2003/0032947 A1 | 2/2003  | Harper et al.       | 2005/0216087 A1  | 9/2005  | Zucherman et al.                  |
| 2003/0040699 A1 | 2/2003  | Talling et al.      | 2005/0266087 A1  | 12/2005 | Junnarkar et al.                  |
| 2003/0044467 A1 | 3/2003  | Brodbeck et al.     | 2005/0271702 A1  | 12/2005 | Wright et al.                     |
| 2003/0045454 A1 | 3/2003  | Okumu et al.        | 2005/0276856 A1  | 12/2005 | Fereira et al.                    |
| 2003/0059376 A1 | 3/2003  | Libbey et al.       | 2005/0281879 A1  | 12/2005 | Chen et al.                       |
| 2003/0059471 A1 | 3/2003  | Compton et al.      | 2006/0013879 A9  | 1/2006  | Brodbeck et al.                   |
| 2003/0060425 A1 | 3/2003  | Ahlem et al.        | 2006/0014678 A1  | 1/2006  | Cowley et al.                     |
| 2003/0078618 A1 | 4/2003  | Fey et al.          | 2006/0030526 A1  | 2/2006  | Liu et al.                        |
| 2003/0097121 A1 | 5/2003  | Jolly et al.        | 2006/0069029 A1  | 3/2006  | Kolterman et al.                  |
| 2003/0104063 A1 | 6/2003  | Babcock et al.      | 2006/0073182 A1  | 4/2006  | Wong et al.                       |
| 2003/0108608 A1 | 6/2003  | Laridon et al.      | 2006/0084604 A1  | 4/2006  | Kitaura et al.                    |
| 2003/0108609 A1 | 6/2003  | Berry et al.        | 2006/0084922 A1  | 4/2006  | Botha                             |
| 2003/0113380 A1 | 6/2003  | Ramstack et al.     | 2006/0094652 A1  | 5/2006  | Levy et al.                       |
| 2003/0114837 A1 | 6/2003  | Peterson et al.     | 2006/0094693 A1  | 5/2006  | Aziz et al.                       |
| 2003/0118660 A1 | 6/2003  | Rickey et al.       | 2006/0106399 A1  | 5/2006  | Taras et al.                      |
| 2003/0135153 A1 | 7/2003  | Hagemeier           | 2006/0141040 A1  | 6/2006  | Chen et al.                       |
| 2003/0138403 A1 | 7/2003  | Drustrup            | 2006/0142234 A1  | 6/2006  | Chen et al.                       |
| 2003/0138491 A1 | 7/2003  | Tracy et al.        | 2006/0160736 A1  | 7/2006  | Nadler                            |
| 2003/0157178 A1 | 8/2003  | Chen et al.         | 2006/0178304 A1  | 8/2006  | Juul-Mortensen et al.             |
| 2003/0170289 A1 | 9/2003  | Chen et al.         | 2006/0193918 A1  | 8/2006  | Rohloff et al.                    |
| 2003/0180364 A1 | 9/2003  | Chen et al.         | 2006/0216242 A1  | 9/2006  | Rohloff et al.                    |
| 2003/0186858 A1 | 10/2003 | Arentsen            | 2006/0224145 A1  | 10/2006 | Gills                             |
| 2003/0191099 A1 | 10/2003 | Bohlmann et al.     | 2006/0233841 A1  | 10/2006 | Brodbeck et al.                   |
| 2003/0211974 A1 | 11/2003 | Brodbeck et al.     | 2006/0246138 A1  | 11/2006 | Rohloff et al.                    |
| 2003/0215515 A1 | 11/2003 | Truong-Le et al.    | 2006/0251618 A1  | 11/2006 | Dennis et al.                     |
| 2003/0220617 A1 | 11/2003 | Dickerson           | 2006/0263433 A1  | 11/2006 | Ayer et al.                       |
| 2003/0233101 A1 | 12/2003 | Lubock et al.       | 2006/0264890 A1  | 11/2006 | Moberg et al.                     |
| 2004/0001689 A1 | 1/2004  | Goldsmith et al.    | 2006/0280795 A1  | 12/2006 | Penhasi et al.                    |
| 2004/0001889 A1 | 1/2004  | Chen et al.         | 2006/0293232 A1  | 12/2006 | Levy et al.                       |
| 2004/0002442 A1 | 1/2004  | Pan et al.          | 2007/0027105 A1  | 2/2007  | Junnarkar et al.                  |
| 2004/0022859 A1 | 2/2004  | Chen et al.         | 2007/0141102 A1  | 6/2007  | De Graaff et al.                  |
|                 |         |                     | 2007/0149011 A1  | 6/2007  | Kent et al.                       |
|                 |         |                     | 2007/0166352 A1  | 7/2007  | Wright et al.                     |
|                 |         |                     | 2007/0207958 A1  | 9/2007  | Bridon et al.                     |

(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0248572 A1 10/2007 Moran et al.  
 2007/0281024 A1 12/2007 Lautenbach et al.  
 2008/0020016 A1 1/2008 Li et al.  
 2008/0038316 A1 2/2008 Wong et al.  
 2008/0064636 A1 3/2008 Bloom et al.  
 2008/0091176 A1 4/2008 Alessi et al.  
 2008/0065090 A1 5/2008 Scribner et al.  
 2008/0110515 A1 5/2008 Angelosanto et al.  
 2008/0112994 A1 5/2008 Junnarkar et al.  
 2008/0194985 A1 8/2008 Nicoson et al.  
 2008/0200383 A1 8/2008 Jennings et al.  
 2008/0207512 A1 8/2008 Roth et al.  
 2008/0208194 A1 8/2008 Bickenbach  
 2008/0226625 A1 9/2008 Berry et al.  
 2008/0226689 A1 9/2008 Berry et al.  
 2008/0260838 A1 10/2008 Hokenson et al.  
 2008/0260840 A1 10/2008 Alessi et al.  
 2008/0269725 A1 10/2008 Deem et al.  
 2008/0312157 A1 12/2008 Levy et al.  
 2009/0012463 A1 1/2009 Beelen et al.  
 2009/0022727 A1 1/2009 Houston et al.  
 2009/0036364 A1 2/2009 Levy et al.  
 2009/0042781 A1 2/2009 Petersen et al.  
 2009/0074734 A1 3/2009 Rottiers  
 2009/0087408 A1 4/2009 Berry et al.  
 2009/0125030 A1 5/2009 Tebbe et al.  
 2009/0156474 A1 6/2009 Roth et al.  
 2009/0163447 A1 6/2009 Maggio  
 2009/0186817 A1 7/2009 Ghosh et al.  
 2009/0202481 A1 8/2009 Li et al.  
 2009/0202608 A1 8/2009 Alessi et al.  
 2009/0209460 A1 8/2009 Young et al.  
 2009/0210019 A1 8/2009 Kim et al.  
 2009/0215694 A1 8/2009 Kolterman et al.  
 2009/0234392 A1 9/2009 Dziejdzic et al.  
 2009/0247463 A1 10/2009 Wright et al.  
 2009/0254143 A1 10/2009 Tweden et al.  
 2009/0286723 A1 11/2009 Levy et al.  
 2009/0312246 A1 12/2009 Baron et al.  
 2010/0092566 A1 4/2010 Alessi et al.  
 2010/0094252 A1 4/2010 Wengreen et al.  
 2010/0105627 A1 4/2010 Salama et al.  
 2010/0144621 A1 6/2010 Kim et al.  
 2010/0185184 A1 7/2010 Alessi et al.  
 2010/0297209 A1 11/2010 Rohloff et al.  
 2010/0298807 A1 11/2010 Jansen et al.  
 2010/0298840 A1 11/2010 Schwartz  
 2010/0331868 A1 12/2010 Bardy  
 2010/0331878 A1\* 12/2010 Kleinwachter .... A61B 17/3468  
 606/205  
 2011/0076317 A1 3/2011 Alessi et al.  
 2011/0091527 A1 4/2011 Moonen et al.  
 2011/0104111 A1 5/2011 Rohloff et al.  
 2011/0152181 A1 6/2011 Alsina-Fernandez et al.  
 2011/0152182 A1 6/2011 Alsina-Fernandez et al.  
 2011/0160708 A1 6/2011 Berry et al.  
 2011/0166554 A1 7/2011 Alessi et al.  
 2011/0264077 A1 10/2011 Rohloff et al.  
 2011/0306549 A1 12/2011 Tatarkiewicz et al.  
 2012/0178687 A1 7/2012 Alessi et al.  
 2012/0208755 A1 8/2012 Leung  
 2012/0265232 A1 10/2012 Surbone  
 2012/0303045 A1 11/2012 Cooper et al.  
 2013/0030417 A1 1/2013 Alessi  
 2013/0034210 A1 2/2013 Rohloff et al.  
 2013/0052237 A1 2/2013 Eliaz et al.  
 2013/0296661 A1 11/2013 Bornzin et al.  
 2013/0324977 A1 12/2013 Vanderpool  
 2014/0058409 A1 2/2014 Bratlie  
 2014/0058425 A1 2/2014 Porat  
 2014/0121741 A1 5/2014 Bennett et al.  
 2014/0148837 A1 5/2014 Levitan  
 2014/0163057 A1 6/2014 Patel et al.  
 2014/0236162 A1\* 8/2014 Barongan ..... A61B 17/50  
 606/99

2014/0257272 A1 9/2014 Clark, III et al.  
 2014/0324067 A1 10/2014 Emken et al.  
 2014/0378900 A1 12/2014 Alessi et al.  
 2015/0111818 A1 1/2015 Alessi et al.  
 2015/0057227 A1 2/2015 Leung  
 2015/0133791 A1 5/2015 Sato et al.  
 2015/0231062 A1 8/2015 Lautenbach et al.  
 2015/0231256 A1 8/2015 Berry et al.  
 2015/0297509 A1 10/2015 Schwarz  
 2015/0359553 A1 12/2015 Harnisch  
 2016/0022582 A1 1/2016 Alessi et al.  
 2016/0030337 A1 2/2016 Kuzma et al.  
 2016/0158577 A1\* 6/2016 Escarguel ..... A61M 37/0069  
 600/1  
 2016/0354115 A1 12/2016 Smith et al.  
 2016/0354305 A1 12/2016 Alessi et al.  
 2017/0056476 A1 3/2017 Rohloff et al.  
 2017/0079906 A1 3/2017 Alessi et al.  
 2017/0119854 A1 5/2017 Alessi et al.  
 2017/0119855 A1 5/2017 Berry et al.  
 2017/0181964 A1 6/2017 Lautenbach et al.  
 2017/0252409 A1 9/2017 Leung  
 2017/0273706 A1 9/2017 Mirza et al.  
 2017/0319470 A1 11/2017 Eliaz et al.  
 2017/0319662 A1 11/2017 Berry et al.  
 2017/0348392 A1 12/2017 Rohloff et al.  
 2017/0368145 A1 12/2017 Alessi et al.  
 2018/0009871 A1 1/2018 Blackwell et al.  
 2018/0185451 A1 7/2018 Young et al.  
 2018/0193059 A1 7/2018 Bae et al.  
 2018/0368875 A1\* 12/2018 Castillo ..... A61B 17/3468

FOREIGN PATENT DOCUMENTS

EP 0295411 12/1988  
 EP 0368339 5/1990  
 EP 0373867 6/1990  
 EP 0431942 6/1991  
 EP 0486959 A1 5/1992  
 EP 0521586 A1 1/1993  
 EP 0379147 9/1994  
 EP 0627231 12/1994  
 EP 0729747 5/1997  
 EP 0771817 5/1997  
 EP 0841359 5/1998  
 EP 0767689 6/1999  
 EP 1046399 10/2000  
 EP 1084703 3/2001  
 EP 1300129 A2 4/2003  
 EP 1300173 A2 4/2003  
 EP 1600187 1/2009  
 EP 2133073 A1 12/2009  
 EP 2020990 9/2010  
 FR 640907 7/1928  
 GB 1049104 11/1966  
 GB 1518683 7/1978  
 JP H02124814 A 5/1990  
 JP H07196479 A 8/1995  
 JP 9241153 9/1997  
 JP 11-100353 4/1999  
 JP 2006/213727 A 8/2006  
 JP 2010-200838 9/2010  
 NL 9100160 8/1992  
 NZ 592113 8/2012  
 TW 200634060 10/2006  
 WO WO 1989/003678 A1 5/1989  
 WO WO 1990/013285 A1 11/1990  
 WO WO 1990/013361 A1 11/1990  
 WO WO 1990/013780 A1 11/1990  
 WO WO 1991/07160 5/1991  
 WO WO 1992/019241 A1 11/1992  
 WO WO 1993/06819 4/1993  
 WO WO 1993/06821 4/1993  
 WO WO 1993/008832 5/1993  
 WO WO 1993/09763 5/1993  
 WO WO 1993/23083 11/1993  
 WO WO 1994/09743 5/1994  
 WO WO 1994/010982 A1 5/1994  
 WO WO 1994/21262 9/1994

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO WO 1995/01167 1/1995  
 WO WO 1995/09006 4/1995  
 WO WO 1995/09007 4/1995  
 WO WO 1995/013799 A1 5/1995  
 WO WO 1995/34285 12/1995  
 WO WO 1996/001134 1/1996  
 WO WO 1996/003116 2/1996  
 WO WO 1996/036317 A1 11/1996  
 WO WO 1996/39142 12/1996  
 WO WO 1996/40049 12/1996  
 WO WO 1996/40139 12/1996  
 WO WO 1996/40355 12/1996  
 WO WO 1997/15289 5/1997  
 WO WO 1997/15296 5/1997  
 WO WO 1997/28181 8/1997  
 WO WO 1997/031943 A1 9/1997  
 WO WO 1997/044039 A1 11/1997  
 WO WO 1997/46204 12/1997  
 WO WO 1997/47339 12/1997  
 WO WO 1998/00152 1/1998  
 WO WO 1998/00157 1/1998  
 WO WO 1998/00158 1/1998  
 WO WO 1998/02169 1/1998  
 WO WO 1997/041837 A3 2/1998  
 WO WO 1998/007412 A1 2/1998  
 WO WO 98/013092 A1 4/1998  
 WO WO 1998/16250 4/1998  
 WO WO 1998/17315 4/1998  
 WO WO 1998/20930 5/1998  
 WO WO 1998/27960 7/1998  
 WO WO 1998/027962 7/1998  
 WO WO 1998/27963 7/1998  
 WO WO 1998/030231 7/1998  
 WO WO 1998/32463 7/1998  
 WO WO 1998/42317 10/1998  
 WO WO 1998/47487 10/1998  
 WO WO 1998/51282 11/1998  
 WO WO 1999/03453 1/1999  
 WO WO 1999/04767 2/1999  
 WO WO 1999/004768 2/1999  
 WO WO 1999/012549 A2 3/1999  
 WO WO 1999/16419 4/1999  
 WO WO 1999/025728 5/1999  
 WO WO 1999/29306 6/1999  
 WO WO 1999/033446 7/1999  
 WO WO 1999/33449 7/1999  
 WO WO 1999/39700 8/1999  
 WO WO 1999/040788 8/1999  
 WO WO 1999/044659 9/1999  
 WO WO 1999/062501 12/1999  
 WO WO 1999/064061 12/1999  
 WO WO 2000/013663 3/2000  
 WO WO 2000/029206 5/2000  
 WO WO 2000/038652 7/2000  
 WO WO 2000/040273 7/2000  
 WO WO 2000/041548 7/2000  
 WO WO 2000/045790 8/2000  
 WO WO 2000/054745 9/2000  
 WO WO 2000/059476 A1 10/2000  
 WO WO 2000/066087 A2 11/2000  
 WO WO 2000/066138 11/2000  
 WO WO 2000/067728 11/2000  
 WO WO 2001/019345 A1 3/2001  
 WO WO 2001/028525 A2 4/2001  
 WO WO 2001/043528 6/2001  
 WO WO 2001/051041 7/2001  
 WO WO 2001/78683 10/2001  
 WO WO 2002/028366 4/2002  
 WO WO 2002/036072 5/2002  
 WO WO 2002/043800 6/2002  
 WO WO 2002/045752 6/2002  
 WO WO 2002/47716 6/2002  
 WO WO 2002/067895 9/2002  
 WO WO 2002/069983 9/2002  
 WO WO 02/083216 10/2002

WO WO 2002/76344 10/2002  
 WO WO 2002/085428 10/2002  
 WO WO 2003/000230 1/2003  
 WO WO 2003/007981 1/2003  
 WO WO 2003/011892 2/2003  
 WO WO 2003/020245 A1 3/2003  
 WO WO 2003/024357 3/2003  
 WO WO 2003/024503 3/2003  
 WO WO 2003/030923 4/2003  
 WO WO 2003/041684 5/2003  
 WO WO 2003/041757 5/2003  
 WO WO 2003/053400 7/2003  
 WO WO 2003/066585 A2 8/2003  
 WO WO 2003/072113 9/2003  
 WO WO 2003/072133 9/2003  
 WO WO 2004/002565 1/2004  
 WO WO 2004/034975 A2 4/2004  
 WO WO 2004/035754 A2 4/2004  
 WO WO 2004/035762 A2 4/2004  
 WO WO 2004/036186 A2 4/2004  
 WO WO 2004/052336 6/2004  
 WO WO 2004/056338 7/2004  
 WO WO 2004/089335 10/2004  
 WO WO 2004/103342 A2 12/2004  
 WO WO 2005/048930 6/2005  
 WO WO 2005/048952 6/2005  
 WO WO 2005/102293 11/2005  
 WO WO 2005/110425 11/2005  
 WO WO 2006/017772 2/2006  
 WO WO 2006/023526 3/2006  
 WO WO 2006/081279 8/2006  
 WO WO 2006/083761 8/2006  
 WO WO 2006/084139 8/2006  
 WO WO 2006/086727 8/2006  
 WO WO 2006/101815 9/2006  
 WO WO 2006/111169 10/2006  
 WO WO 2006/131730 12/2006  
 WO WO 2007/024700 3/2007  
 WO WO 2007/056681 5/2007  
 WO WO 2007/075534 7/2007  
 WO WO 2007/084460 7/2007  
 WO WO 2007/133778 11/2007  
 WO WO 2007/140416 12/2007  
 WO WO 2008/021133 2/2008  
 WO WO 2008/041245 A2 4/2008  
 WO WO 2008/061355 5/2008  
 WO WO 2008/133908 11/2008  
 WO WO 2008/134425 11/2008  
 WO WO 2009/109927 9/2009  
 WO WO 2009/143285 A2 11/2009  
 WO WO 2011/011697 1/2011  
 WO WO 2013/004983 A1 1/2013  
 WO WO 2013/118109 A1 8/2013  
 WO WO 2013/160347 10/2013

## OTHER PUBLICATIONS

Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-Alpha2a in pediatric patients with refractory cancer," *J. Clin. Oncol.* 15(11):3330-3337 (Nov. 1997).  
 Adolf et al., "Antigenic structure of human interferon  $\omega 1\alpha 11$  (Interferon all 1): comparison with other human interferons," *J. Gen. Virol.* 68(6):1669-1676 (Jun. 1987).  
 Adolf et al., "Human interferon  $\omega 1$ : isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," *Biochim. Biophys. Acta* 108(9):167-174 (Jun. 1991).  
 Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN)  $\omega 1$ : evidence that IFN- $\omega 1$  is a component of human leukocyte IFN," *Virology* 175(2):410-471 (Apr. 1990).  
 Adolf et al., "Purification and characterization of natural human interferon  $\omega 1$ ," *J. Bio. Chem.* 265(16):9290-9295 (Jun. 1990).  
 Adolf, "Human interferon omega-a review," *Mult. Sclr.* 1:S44-47 (1995).



(56)

## References Cited

## OTHER PUBLICATIONS

- Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" *Journal of Medicinal Chemistry*, vol. 44, No. 19, (2001): 3109-3116.
- Akers, et al., "Formulation Design and Development of Parenteral Suspensions," *Journal of Parenteral Science & Technology*, 41(3): 88-96 (1987).
- Alonso et al. "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," *Pharmaceutical Research*, 10(7): 945-953 (1993).
- Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
- Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
- Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
- ASTM International, *AnnualBook of ASTM Standards*, 8.02:208-211, 584-587 (1984).
- Aulitzky, "Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," *Journal of Clinical Oncology* 7(12):1875-1884 (1989).
- Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," *Bioconjugate Chemistry* 12(2):195-202 (2001).
- Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," *J. Pharm. Sci.*, 85(9):908-914 (1996).
- Bakhtiar et al, "Taking Delivery," *Soap Perfumery & Cosmetics* 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
- Balkwill,F., "Interferons," *Lancet* 1(8646):1060-1063 (May 1989).
- Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," *Drug Dev. & Industrial Pharmacy* 10(5):699-712 (1984).
- Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," *Hepatology* 33(2):419-423 (Feb. 2001).
- Bell et al, "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," *Drug Delivery Research & Dev. Biopolymers*, (35):201-209 (1995).
- Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," *Nature* 302:716-718 (1983).
- Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," *Int. J. Radiat. Biol.* 67(1):57-64 (1995).
- Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," *International Journal of Pharmaceutics*, 43(1-2): 179-186 (Apr. 1988).
- Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," *Euro. J. Pharm. Sci.* 2(4):271-279 (1994).
- Bolinger et al., "Recombinant interferon  $\gamma$  for treatment of chronic granulomatous disease and other disorders," *Clin. Pharm.* 11(10):834-850 (Oct. 1992).
- Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," *Can. J. Gastroenterol.* 14(Supp. B):21B-29B (Jul.-Aug. 2000).
- Borden et al., "Second-generation interferons for cancer: Clinical targets," *Semin. Cancer Biol.* 10(2):125-144 (Apr. 2000).
- Boué et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN- $\omega$ 1 obtained from *Pichia pastoris*," *J. Interferon & Cytokine Res.* 20:677-683 (2000).
- Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
- Buckwold et. al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," *Antiviral Res.* 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
- Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anathermal solvents: fluid phase coexistence," *J. Chem. Physics* 104(20):8082-8095 (1996). CAS Number: 56-81-5 (Nov. 16, 1984).
- Cha and Pitt, "A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules," *Journal of Controlled Release*, 7: 69-78 (1988).
- Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," *Journal of Controlled Release*, 8: 259-265 (1989).
- Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," *Pharm. Tech.* 20(1):80-84 (1996).
- Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," *Chem. & Physics of Lipids* 1(5):445-475 (1967).
- Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," *Methods & Findings in Experimental & Clinical Pharmacology* 20(3):211-215 (1998).
- Clark et al., "The diabetic Zucker fatty rat," *Proc. Soc. Exp. Biol.* 173(1):68-75 (1983).
- Cohen et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," *Pharmaceutical Research*, 8(6): 713-720 (1991).
- Condino-Neto, "Interferon- $\gamma$  improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," *Blood* 95(11):3548-3554 (Jun. 2000).
- Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," *Journal of Microencapsulation*, 9(2): 153-166 (1992).
- Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," *J. Pharm. Sci.* 91:388-395 (2002).
- Darney, "Subdermal progestin implant contraception," *Current Opinion in Obstetrics & Gynecology* 3:470-476 (1991).
- Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," *BioPharm*, 2(11):44-51 (1999).
- Dash et al., "Therapeutic applications of implantable drug delivery systems," *Journal of Pharmacological and Toxicological Methods*, 40(1):1-12 (1998).
- Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis.*, Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ).
- Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," *Am. J. Physiol. Endocrinol. Metab.*, 282:E873-E879 (2002).
- Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," *J. Am. Chem. Soc.* 116(21):9420-9422 (1994).
- Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose  $\alpha$ -2B interferon plus ribavirin for 6 or 12 months," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis.*, Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
- Dorr et al., "Phase I-II trial of interferon-Alpha 2b by continuous subcutaneous infusion over 28 days," *J. Interferon Res.* 8:717-725 (1988).
- Efendic et al., "Overview of incretin hormones," *Horm. Metab. Res.*, 36(11-12):742-746 (2004).
- Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," *Life Sci.*, 55(8):629-634 (1994).
- Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon- $\alpha$  for the treatment of patients with advanced

(56)

## References Cited

## OTHER PUBLICATIONS

- renal cell carcinoma: a southwest oncology group Phase II study," *Cancer* 89(3):597-603 (Aug. 2000).
- Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from *Heloderma suspectum* venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," *J. Biol. Chem.*, 267(11):7402-7405 (1992).
- Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from *Heloderma horridum* venom," *J. Biol. Chem.*, 265(33):20259-20262 (1990).
- Eppstein et al., "Biological activity of liposome-encapsulated murine interferon  $\gamma$  is mediated by a cell membrane receptor," *PNAS USA* 82:3688-3692 (1985).
- Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," *Proc.-Conf. Colloid Chem.* 193-196 (1993).
- Erowid, "Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages.
- Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," *Vaccine* 14(9):879-885.(1996).
- Fang et al., "The impact of baseline liver histology on virologic response to interferon a-2b $\pm$ p ribavirin therapy in patients with chronic hepatitis C," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis.*, Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
- Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," *J. Nutritional Biochem.* 4(1):630-634 (1993).
- Ferenci et al., "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977)*.
- Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon a," *Lancet* 356(9223):41 (Jul. 2000).
- Franchetti et al., "Furanfuran and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," *J. Medicinal Chem.* 38(19):3829-3837 (1995).
- Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," *Int'l J. Pharmaceutics* 222(1):57-64 (2001).
- Fujii et al., "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)," *Int'l J. Pharmaceutics* 234(1-2): 121-128 (2002).
- Gao et al., "Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans," *Drug Metabolism and Disposition*, vol. 40, No. 5, pp. 990-997 (2012).
- Gan To Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," *Cancer & Chemotherapy* 12(4):913-920 (Apr. 1985) (non-English with English abstract).
- Gappa et al., "Juvenile laryngeal papillomatosis—a case report," *Pneumologie* 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
- Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," *J. Clin. Oncol.* 14(8):2234-2241 (Aug. 1996).
- Georgios, et al. "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers," *Advances in Therapy, Health Communications, Metuchen, NJ, US*, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661.
- Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" *Diabetologia* 27:599600 (1984).
- Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis.*, Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
- Glumetza Brochure 2009, 13 Pages.
- Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," *J. Biol. Chem.*, 268(26):19650-19655 (1993).
- Gonzales et al., "Randomized controlled trial including an initial 4-week 'induction' period during one year of high-dose interferon a-2B treatment for chronic hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975)*.
- Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," *Salud Publica Mex* 55:462-468 (2013).
- Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon Alpha," *Cancer Chemother. Pharmacol.* 37(1-2):39-46 (1995).
- Grant et al., "Combination therapy with interferon-a plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," *J. Med. Virol.* 61(4):439442 (Aug. 2000).
- Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," *N. Engl. J. Med.*, 326(20):1316-1322 (1992).
- Hageman, "The Role of Moisture in Protein Stability," *Drug Dev. & Ind. Pharm.* 14(14):2047-2070 (1988).
- Hauck, "Engineer's Guide to Plastics," *Materials Engineering* 5(72):38-45 (Jul. 17, 1972).
- Heathcote et al., "Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," *New England J. Med.* 343(23):1673-1680 (2000).
- Heim et al., "Intracellular signaling and antiviral effects of interferons," *Dig. Liver Dis.* 32(3):257-263 (Apr. 2000).
- Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," *Endocrinol.*, 115:2176-2181 (1984).
- Hellstrand et al., "Histamine and cytokine therapy," *Acta Oncol.* 37(4):347-353 (1998).
- Hellstrand et al., "Histamine and the response to IFN-a in chronic hepatitis C," *Interferon Cytokine Res.* 18(1):21-22 (Jan. 1998).
- Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," *Cancer Immunol Immunother.* 39(6):416-419 (Dec. 1994).
- Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, 21 pages (Sep. 20-24, 2010).
- Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," *J. Toxicol. Sci.*, 18(3):1-9 (1993).
- Hodgman, et al., Eds., *Handbook of Chemistry and Physics*, 35th Edition, 1024-1025 (1953).
- Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," *InterNational Journal of Pharmaceutics*, 146(1):81-92 (1997).
- Hoffmann-La Roche Inc., *Pegasys® (peginterferon alfa-2a)*, 15 pages (2002).
- Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" *Cancer Res* 59(16):4064-4068 (Aug. 1999).
- Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" *Leukemia* 11 Suppl 5:S47S51 (Dec. 1997).
- Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," *Antimicrobial Agents & Chemotherapy*, 26(4):476-480 (1984).
- Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," *Am. J. Clin. Oncol.* 18(1):27-31 (1995).
- IFNB Multiple Sclerosis Study Group, "Interferon $\beta$ -1b is effective in relapsing-remitting multiple sclerosis," *Neurology* 43(4):655-667 (Apr. 1993).
- INTERMUNE® Inc., *Infergen® (Interferon alfacon-1)*, 5 pages (2002).
- Isaacs et al., "Virus interference. I. The interferon," *Pro. R. Soc. Lond. B. Biol. Sci.* 147:258-267 (1957).

(56)

## References Cited

## OTHER PUBLICATIONS

- Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," *J. Vet. Med. Sci.* 60(8):911-917 (1998).
- Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," *J. Microencapsulation* 17(3):343-362 (2000).
- Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," *Journal of Microencapsulation*, 7(3): 297-325 (Jul.-Sep. 1990).
- Johnson et al., "How interferons fight disease," *Sci. Am.* 270(5):68-75 (May 1994).
- Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," *The Oncologist* 12(9):1143-1150 (2007).
- Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
- Kabalnov et al., "Phospholipids as Emulsion Stabilizers. 2. Phase Behavior Versus Emulsion Stability," *Journal of Colloid and Interface Science* 184(1):227-235 (1996).
- Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," *Am. J. Gastroenterol.* 95(5):1284-1289 (May 2000).
- Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," *J. Pharma. Sci.* 29(11):1634-01637 (Nov. 17, 1970).
- Kirkwood et al., "Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," *J. Clin. Oncol.* 14(1):7-17 (1996).
- Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon- $\gamma$ ," *Drug Des. Deliv.* 6(3):157-0167 (Sep. 1990).
- Knepp et al., "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," *J. Pharm. Sci. Tech.* 50(3):163-171 (1996).
- Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human Alpha interferon at elevated temperatures," *Pharm. Res.* 15(7):1090-1095 (1998).
- Knobler et al., "Systemic  $\alpha$ -interferon therapy of multiple sclerosis," *Neurology* 34(10):1273-1279 (Oct. 1984).
- Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant  $\alpha$ -2 interferon," *Maksic Dj Vojnosanit. Pregl.* 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
- Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon  $\beta$ -1b therapy in patients with MS," *Neurology* 54(1):193-199 (Jan. 2000).
- Krown et al., "Interferons and interferon inducers in cancer treatment," *Semin. Oncol.* 13(2):207-217 (1986).
- Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon- $\omega$ ," *J. Interferon Res.* 14:57-59 (1994).
- Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon- $\omega$ -mediated inhibition of human immunodeficiency virus replication," *J. Interferon Cytokine Res.* 16(11):919-927 (Nov. 1996).
- Larsson, "Stability of emulsions formed by polar lipids," *Progress in the Chemistry of Fats and Other Lipids* 16:163-0169 (1978).
- Lee and Timasheff, "The stabilization of proteins by sucrose," *J. Biological Chem.*, 256(14): 7193-7201 (Jul. 1981).
- Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," *Prog. Abstr. Dig. Dis. Week 2000*, San Diego, CA (May 21-24, 2000) (Abstract 974).
- Lee, "Therapy of hepatitis C: interferon alfa-2A trials," *Hepatology* 26: 89S-95S (Sep. 1997) (XP000981288).
- Li et al. "Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in *Current Therapeutic Research*, vol. 71, No. 4, Aug. 2010.
- Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," *Journal of Controlled Release*, 37: 199-214 (1995).
- Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," *Proc. Natl. Acad. Sci. USA*, 80(18):5485-5489 (1983).
- Lublin et al., "Defining the Clinical course of multiple sclerosis: results of an International survey," *Neurology*. 46:907-911 (1996).
- Lukaszewski et al., "Pegylated a interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," *J. Virol.* 74(11):5006-5015 (Jun. 2000).
- Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," *Proc. Natl. Acad. Sci. USA*, 79(2):345-349 (1982).
- Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," *J. Pharm. & Pharmacol.* 49(1):16-21 (1997).
- Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," *Journal of Microencapsulation*, 13(4): 419-433 (Jul.-Aug. 1996).
- Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preClinical and Clinical results," *Best Practice & Research Clinical Endocrinology & Metabolism* 23:463-77 (2009).
- Magnuson et al. "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," *Protein Expression & Purification* 7:220-228 (1996).
- Malley et al., "Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration," *Drug Chem Toxicol.* 24(4):315-38 (Nov. 2001).
- Manning et al., "Stability of protein Pharmaceuticals," *Pharm. Res.* 6(11):903-918 (1989).
- Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," *J. Clinical Oncol.* 13(5):1110-1122 (1995) (XP009078965).
- Massey, "Interaction of vitamin E with saturated phospholipid bilayers," *Biochem. & Biophys. Res. Comms.* 106(3):842-847 (1982).
- Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," *Journal of Controlled Release*, 3: 103-117 (1986).
- Mchutchison et al., "Interferon  $\alpha$ -2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," *N. Engl. J. Med.* 339(21):1485-1492 (Nov. 1998).
- Mehta, et al., "Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," *Journal of Controlled Release*, 41: 249-257 (1996).
- Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," *Am. J. Physiol. Endocrinol. Metab.*, 290(6):E1118-E1123 (2006).
- Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN- $\alpha$  plus IL-2 and IL-12)," *J. Immunother.* 23(3):369-378 (May-Jun. 2000).
- Milella et al., "Neutralizing antibodies to recombinant  $\alpha$ -interferon and response to therapy in chronic hepatitis C infection," *Liver* 13(3):146-150 (Jun. 1993).
- Mohler, "Primer on electrodeposited coatings," *Materials Engineering* 5:38-45 (1972).
- Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," *Int. J. Peptide Protein Research*, 40:333-343 (1992).
- Morgan, "Structure and Moisture Permeability of Film-Forming Polymers," *Ind. Eng. Chem.* 45(10):2296-2306 (1953).
- Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," *J. Clinical Oncol.* 19(5):1312-1319 (2001).

(56)

## References Cited

## OTHER PUBLICATIONS

- Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," *Diabet. Med.*, 15(11):937-945(1998).
- Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," *Science* 282:103-107 (Dec. 1998).
- Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-a-2a and a polyethylene glycol-modified derivative in healthy subjects," *Clin. Pharmacol. Ther.* 59(6):636-646 (Jun. 1996).
- Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," *Drug Discovery Today* 10(10):703-710 (May 15, 2005).
- Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o/w emulsion for intravenous administration," *Eur. J. Pharm. Sci.* 13(4):393-401 (2001).
- Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," *Esp. Quimioter.* 12(3):220-228 (Sep. 1999) (non-English with English abstract).
- Ortiz et al., "A differential scanning calorimetry study of the interaction of a-tocopherol with mixtures of phospholipids," *Biocim et Biophys Acta* 898(2):214-222 (1987).
- Palmeri et al., "5-Fluorouracil and recombinant a-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," *J. Chemotherapy* 2(5):327-330 (Oct. 1990).
- Panitch, "Interferons in multiple sclerosis," *Drugs* 44(6):946-962 (Dec. 1992).
- Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two year study," *Acta. Neurol. Scand.* 100:283-289 (1999).
- Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," *Neurology* 43:662-667 (1993).
- Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," *Nature*, 282:260-266 (1979).
- PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
- Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," *Frontiers in diabetes research. Lessons from Animal Diabetes III*, Shafir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
- Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," *ILAR Journal*, 32(3):16-19 (1990).
- Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000*, San Diego, CA (May 21-24, 2000) (Abstract 973).
- Plauth et al., "Open-label phase II study of omega interferon in previously untreated HCV infected patients," *Hepatology* 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
- Plauth et al., "Open-label study of omega interferon in previously untreated HCV-infected patients," *J. Hepatology* 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
- Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," *J. Biol. Chem.*, 273(16):9778-9784 (1998).
- Poynard et al., "Is an 'a la carte' combined interferon a 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," *Hepatology* 31(1):211-218 (Jan. 2000).
- Poynard et al., "Randomized trial of interferon a 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," *Lancet* 352(9138):1426-1432 (Oct. 1998).
- Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," *Rev. Diabet. Stud.*, 5(2):73-94 (2008).
- Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987).
- Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," *US Endocrinology* 7(2):104-109 (2011).
- Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," *Pharm. Res.* 14(2):119-127 (1997).
- Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon Alpha-2a and BCNU for patients with high-grade glioma," *Int'l J. Radiat. Oncol. Biol. Phys.* 40(2):297-302 (Jan. 15, 1998).
- Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial," *Diabetic Medicine* 27(9):1024-1032 (Sep. 2010).
- Roberts et al., "The Evolution of the Type I Interferons 1," *J. Interferon Cytokine Res.* 18(10):805-816 (Oct. 1998).
- Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
- Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971).
- Rogers et al., "Permeability Valves," *Ind. & Eng. Chem.* 49(11):1933-1936 (Nov. 17, 1957).
- Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," *J. Diabetes Sci. & Tech.*, 2(3):461-467 (May 1, 2008).
- Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," *Transplantation* 48(4):554-558 (1989).
- Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," *Endocrinol.* 148(12):6054-61 (Dec. 2007).
- Roth et al., "High Dose Etrinate and Interferon-Alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," *Acta Oncol.* 38(5):613-617 (1999).
- Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," *Pharmaceutical Research*, 13(3): 360-367 (1996).
- Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," *Pharmaceutical Research*, 5(1): 21-30 (1988).
- Schepis et al., "Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection," *Hepatology*, 33(2); 333-338 (2001).
- Schepp et al., "Exendin-4 and exendin-(9-39)NH<sub>2</sub>: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH<sub>2</sub>," *Eur. J. Pharmacol.*, 269(2):183-191 (1994).
- Schering Corp., Intone® A for Injection, 6 pages (2001).
- Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
- Schmalhub et al., "Modification of drug penetration into human skin using microemulsions," *J. Controlled Release* 46(3):279-285 (1997).
- Sen et al., "The interferon system: a bird's eye view of its biochemistry," *J. Biol. Chem.* 267(8):5017-5020 (Mar. 1992).
- Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," *J. Gastroenterol. Hepatol.* 15(3):294-299 (Mar. 2000).
- Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," *Ann. Int. Med.* 132(7):517-524 (Apr. 2000).
- Shire et al., "Challenges in the Development of High Protein Concentration Formulations," *J. Pharm. Sci.* 93:1390-1402 (2004).
- Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon 131a," *Neurology* 55(2):185-192 (Jul. 2000).
- Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).

(56)

## References Cited

## OTHER PUBLICATIONS

Sparks et al., "Lipoprotein Alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," *Metabolism*, 47(11):1315-1324 (1998).

Sulkowski et al., "Peginterferon-a-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," *Biodrugs* 16(2):105-109 (2002).

Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," *Endocrinology*, 141(6): 1936-1941 (2000).

Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon Alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," *Blood* 98(6):1708-1713 (2001).

Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," *Endocrinology* 146(9): 3748-56 (Sep. 2005).

Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," *Int. J. Cancer* 87(5):741-749 (Sep. 2000).

Taylor et al. "Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes," *Horm. Metab. Res.* 37: 627-632 (2005).

Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," *Eur. J. Pharm. Biopharm.*, 42(1): 16-24 (1996).

Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," *Journal of Controlled Release* 43(1):9-22 (1997).

Tong et al., "Prediction of response during interferon a 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," *Hepatology* 26(6):1640-01645 (Dec. 1997).

Touza Rey et al., "The Clinical response to interferon-y in a patient with chronic granulomatous disease and brain abscesses due to *Aspergillus fumigatus*," *Ann. Med. Int.* 17(2):86-87 (Feb. 2000).

Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro," *Biomaterials*. 20(11): 1057-1062 (1999).

Trudeau et al., "A phase I study of recombinant human interferon Alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," *Cancer Chemother. Pharmacol.* 35(6):496-500 (1995).

Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," *PNAS USA*, 90(5):1992-1996 (1993).

Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," *J. Pharm. Sci.* 86(5):603-7 (May 1997).

Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," *Diabetologia; Clinical and Experimental Diabetes and Metabolism* 49(8):1915-1923 (Jun. 27, 2006).

van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," *J. Clin. Endocrin. Metab.*, 82(11): 3597-3602 (1997).

Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating

factor support for advanced malignancies of the chest," *Cancer Chemother. Pharmacol.* 35(4):304-312 (1995).

Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," *Otolaryngol. Head Neck Surg.*, 118(3 Pt. 1):304-308 (1998).

Wang et al, "Parenteral formulations of proteins and peptides: stability and stabilizers," *J. Parenter. Sci. Technol.* 42(2S):S4-S26 (1988).

Wang et al., "Preferential interaction of a-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," *Eur. J. Biochem.* 267(21):6362-6368 (2000).

Wang et al., "Ripple phases induced by a-tocopherol in saturated diacylphosphatidylcholines," *Archives of Biochem. & Biophys.* 377(2):304-314 (2000).

Wang et al., "The distribution of a-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," *Biochimica et Biophysica Acta-Biomembranes* 1509(1-2):361-372 (2000).

Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011).

Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*)," *Diabetes*, 48(5):1026-1034 (1999).

Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with a interferons, in the treatment of chronic hepatitis C," *Semin. Liver Dis.* 19(Supp. 1):95-102 (1999).

Yu et al. "Glucagon-like peptide 1 based therapy for type 2 diabetes," *World Journal of Pediatrics* vol. 4, No. 1, Feb. 1, 2008, pp. 8-13.

Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," *J. Pharm. Sci.* 85(4):396-401 (1996).

Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," *Antivir. Res.* 11(3):147-0160 (Apr. 1989).

Zein, "Interferons in the management of viral hepatitis," *Cytokines Cell Mol. Ther.* 4(4):229-241 (Dec. 1998).

Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon a on viral turnover," *Hepatology* 28(1):245-252 (Jul. 1998).

Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," *New Engl. J. Med.* 343(23):1666-1672 (2000).

Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," *Current Physician* 2(12):45-46 (1997).

Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," *J. Clinical Pediatrics* 14(2):83-84 (1996).

Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," *Beijing Med. J.* 13(2):80-81 (1998).

Ziesche et al., "A preliminary study of long-term treatment with interferon y-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," *New Engl. J. Med.* 341(17):1264-1269 (Oct. 1999).

\* cited by examiner




FIG. 1




FIG. 2




FIG. 3






FIG. 4




FIG. 5




FIG. 6




FIG. 7